Setmelanotide
Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome
Rhythm · Phase 2 · Completed · Enrollment 40
No selected arm has a reported week for this endpoint.
A solid line connects the weeks the source reports.